Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0TBBXF
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Anti-CD47 mAb (IgG2b/kappa)-DM1
|
|||||
| Synonyms |
Anti-CD47 mAb DM1
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Triple negative breast cancer [ICD11:2C60-2C65]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4-5
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-CD47 mAb (IgG2b/kappa)-
|
Antibody Info | ||||
| Antigen Name |
Leukocyte surface antigen CD47 (CD47)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM1
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
|
Linker Info | ||||
| Conjugate Type |
The succinimide of SMCC randomly reacts with the free amino groups of lysine residues in mab, forming a stable amide bond.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.